open access
Emicizumab (Hemlibra®) in hemophilia A patients with inhibitors against factor VIII — guidelines of the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine
open access
Abstract
In this document, the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine presents the guidelines for the use of emicizumab. Emicizumab (Hemlibra®, F. Hoffmann — La Roche, Basel, Switzerland) has been licensed for use in the European Union in 2018. In Poland, this medicinal product has been available for patients with congenital hemophilia A and inhibitors against factor VIII since March 2020. This paper is a supplement to the 2017 guidelines for management of patients with haemophilia A and B and inhibitors against factor VIII or IX.
Abstract
In this document, the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine presents the guidelines for the use of emicizumab. Emicizumab (Hemlibra®, F. Hoffmann — La Roche, Basel, Switzerland) has been licensed for use in the European Union in 2018. In Poland, this medicinal product has been available for patients with congenital hemophilia A and inhibitors against factor VIII since March 2020. This paper is a supplement to the 2017 guidelines for management of patients with haemophilia A and B and inhibitors against factor VIII or IX.
Keywords
emicizumab; haemophilia A; inhibitor; prophylaxis; bleeding; guidelines; Poland; factor VIII; by-passing agents; rFVIIa; aPCC
About this articleTitle
Emicizumab (Hemlibra®) in hemophilia A patients with inhibitors against factor VIII — guidelines of the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine
Journal
Journal of Transfusion Medicine
Issue
Article type
Guidelines / Expert consensus
Pages
165-175
Published online
2020-12-03
DOI
10.5603/JTM.2020.0006
Bibliographic record
Journal of Transfusion Medicine 2020;13(3):165-175.
Keywords
emicizumab
haemophilia A
inhibitor
prophylaxis
bleeding
guidelines
Poland
factor VIII
by-passing agents
rFVIIa
aPCC
Authors
Jerzy Windyga
Krzysztof Chojnowski
Anna Klukowska
Paweł Łaguna
Magdalena Łętowska
Andrzej Mital
Wojciech Młynarski
Jacek Musiał
Jacek Treliński
Anetta Undas
Tomasz Urasiński
Joanna Zdziarska
Maria Podolak-Dawidziak